EDMONTON, April 21 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced that Mr. Shawn McMillan, CA has joined the Company as Controller. Mr. McMillan assumes responsibility for the accounting and financial functions of Ceapro and will be instrumental in assisting with future financings. "We are pleased to welcome Shawn to the Ceapro team at an important time in the Company's evolution," said Dr. Mark Redmond, President and CEO. "Our business is focused on growth and as we roll out new products such as CeaProve(TM), our diabetes management technology, Shawn will play a leading role in our financial and strategic planning activities." Mr. McMillan earned his Bachelor of Commerce degree in Accounting from the University of Alberta in 2002. He gained experience in public company reporting and accounting with Deloitte & Touche LLP in Edmonton, Alberta and obtained his Chartered Accountant designation in 2005. 2004 Financial Results and Annual and Special Meeting Ceapro will release its 2004 financial results on or before April 29, 2005. The Company's annual report, containing Management's Discussion and Analysis and Audited Financial Statements, will be mailed to shareholders on or about May 2, 2005. Ceapro's annual and special meeting of shareholders will be held on Wednesday, June 1, 2005, at Lister Centre, University of Alberta, at 3:00 p.m. MDT About Ceapro Inc. Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources. Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing Companies for 2004 and 2005 and is one of Profit Magazine's Next 100 Companies. Ceapro is also the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro's shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.30. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward- looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro announces new Controller
Earlier from Ceapro
Later from Ceapro
- Ceapro receives further investment from AVAC Ltd.
- Ceapro announces 2004 financial results
- Ceapro to present at BioFinance conference
- Ceapro Announces Highlights of Today's Annual General and Special Meeting
- Ceapro announces officer appointment
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro